HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Legend Biotech (NASDAQ:LEGN), maintaining a price target of $87. This reaffirmation underscores the firm's positive outlook on the company's stock.

April 16, 2024 | 5:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Legend Biotech, with a maintained price target of $87, indicating a strong positive outlook.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an uptick in the stock's price in the short term, as the market reacts to the reaffirmed positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100